NL003
PreclinicalSmall molecule
NL003 is one of 39 small molecule programs targeting Ischemia. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
47 competitors in Ischemia
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Lovenox
SanofiApproved
Corlanor
AmgenApproved
Repatha
AmgenApproved
Remodulin
United TherapeuticsApproved
Taxol
TevaApproved
Bayer Aspirin
BayerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Persantine
Boehringer IngelheimApproved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NL003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details